Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Innovent Acquires Rights to KRAS G12C Candidate in $312 Million Pact

Suzhou Innovent acquired greater China rights to GenFleet's lead KRAS G12C oncology candidate in a $312 million agreement. GenFleet is a Shanghai clinical-stage biotech focused on novel oncology and immunology targets. Innovent will pay $22 million upfront, invest $50 million in global development support (if Innovent exercises its global option), and make up to $240 million in milestone payments. GenFleet's KRAS G12C candidate, GFH925, was recently approved to start China trials in patients with cancers that have a KRAS G12C mutation. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.